title: Recurrence of infantile hemangiomas treated with propranolol.
abstract: Propranolol has shown to be effective in the treatment of infantile hemangiomas (IH), but several cases of recurrences have been reported so far. We describe five cases of IH recurrence after propranolol treatment was stopped in 26 patients treated with propranolol all of whom were observed for at least 9 months after treatment was discontinued. Recurrence was present in 5 of 26 cases, yielding a recurrence rate of 19%. All cases were in females. Time from withdrawal to recurrence ranged from 0 to 6 months. In four of five cases, the lesion relapsed after the age of 11 months. Four of the five cases presented partial recurrences, whereas in one case, recurrence was complete. In the majority of cases, recurrence appeared in the deep component of the IH. Early treatment withdrawal or a long proliferative phase of IH are potential causes of hemangioma recurrence, although the exact mechanism remains unclear. The vascular endothelial growth factor receptor might be involved, as well as incomplete apoptosis during treatment.
authors.affiliation: Department of Dermatology, Hospital del Niño Jesús, Madrid, Spain.
authors.forename: Lorea
authors.initials: L
authors.lastname: Bagazgoitia
authors.affiliation: Department of Dermatology, Hospital del Niño Jesús, Madrid, Spain.
authors.forename: Ángela
authors.initials: Á
authors.lastname: Hernández-Martín
authors.affiliation: Department of Dermatology, Hospital del Niño Jesús, Madrid, Spain.
authors.forename: Antonio
authors.initials: A
authors.lastname: Torrelo
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D005260:Female; D018324:Hemangioma, Capillary / Q000188:drug therapy*; D006801:Humans; D007223:Infant; D008297:Male; D009386:Neoplastic Syndromes, Hereditary / Q000188:drug therapy*; D011433:Propranolol / Q000627:therapeutic use*; D012008:Recurrence; D012878:Skin Neoplasms / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D000319:Adrenergic beta-Antagonists; D011433:Propranolol
references.citation: Bayliss SJ, Berk DR, Van Hare GF et al. Re: propranolol treatment for hemangioma of infancy: risks and recommendations. Pediatr Dermatol 2010;27:319-320.
references.citation: Lawley LP, Siegfried E, Todd JL. Propranolol treatment for hemangioma of infancy: risks and recommendations. Pediatr Dermatol 2009;26:610-614.
references.citation: Bagazgoitia L, Torrelo A, Lopez G et al. Propranolol for infantile hemangiomas. Pediatr Dermatol 2011;28:108-114.
references.citation: Leaute-Labreze C, Dumas de la RE, Hubiche T et al. Propranolol for severe hemangiomas of infancy. N Engl J Med 2008;358:2649-2651.
references.citation: Sans V, de la Roque ED, Berge J et al. Propranolol for severe infantile hemangiomas: follow-up report. Pediatrics 2009;124:e423-e431.
references.citation: Brandling-Bennett HA, Metry DW, Baselga E et al. Infantile hemangiomas with unusually prolonged growth phase: a case series. Arch Dermatol 2008;144:1632-1637.
references.citation: Storch CH, Hoeger PH. Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action. Br J Dermatol 2010;163:269-274.
references.citation: Itinteang T, Brasch HD, Tan ST et al. Expression of components of the renin-angiotensin system in proliferating infantile haemangioma may account for the propranolol-induced accelerated involution. J Plast Reconstr Aesthet Surg 2010;64:759-765.
references.citation: Lamy S, Lachambre MP, Lord-Dufour S et al. Propranolol suppresses angiogenesis in vitro: inhibition of proliferation, migration, and differentiation of endothelial cells. Vascul Pharmacol 2010;53:200-208.